Has Richard Rogers received payments from drug or device companies?

Yes. Drug and device makers reported $400,335 in general payments to Richard Rogers across 399 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Richard Rogers did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Richard Rogers come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Richard Rogers

Clinical Genetics (M.D.) · Greenville, SCNPI 1760473524

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $333,585 of the $400,335 with a category attached, or 83.3%. Sanofi accounts for 99.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $97,419 and has fallen 54.8% since, to $44,071 in 2025.

$400,335in general payments, 2019–2025

Across 399 payments — averaging $1003.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$400K
Spark Therapeutics, Inc.$119
Biomarin Pharmaceutical Inc.$115
Takeda Pharmaceuticals U.S.A., Inc.$44
Saol Therapeutics Inc.$27
Ultragenyx Pharmaceutical Inc.$26
plus $56 from 4 others

$13,080in research payments, 2019–2025

Across 15 payments — averaging $872.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$9K
Shire North American Group Inc$3K
Sanofi US Services Inc.$600

What the payments were for

Speaking & faculty fees$333,58583%
Travel & lodging$59,06515%
Food & beverage$7,6822%
Education$20%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	387	$399,948
Spark Therapeutics, Inc.	1	$119
Biomarin Pharmaceutical Inc.	2	$115
Takeda Pharmaceuticals U.S.A., Inc.	2	$44
Saol Therapeutics Inc.	1	$27
Ultragenyx Pharmaceutical Inc.	1	$26
Shire North American Group Inc	1	$19
Amicus Therapeutics, Inc.	1	$19
Sanofi-aventis U.S. LLC	1	$15
Travere Therapeutics, Inc.	2	$2

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NEXVIAZYME$126,202
FABRAZYME$123,093
LUMIZYME$80,421
CERDELGA$58,202
CEREZYME$58,202
ALDURAZYME$13,847
NO PRODUCT DISCUSSED$906
Vimizim$102
Naglazyme$102
Brineura$102

How this compares

Too few clinical genetics (m.d.) providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Other clinical genetics (m.d.) in Greenville

Emily BlackGreenville$549
David EvermanGreenville$186
Neena ChampaigneCharleston$31K
Kristen LancasterCharleston$6K
Steven SkinnerGreenwood$6K
Michael LyonsNorth Charleston$501
Steven ShapiroCharleston$470
Elliot StolermanNorth Charleston$452
Richard SchroerNorth Charleston$393
Sara CatheyNorth Charleston$307

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →